Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
inJun 16, 2022
Presented at the ASCO annual meeting 2022
Read more
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
inOct 25, 2021
Published in Nature Cancer, October 2021
A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer
inSep 29, 2021
Presented at the ESMO annual meeting 2021
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2
inApr 12, 2021
Presented at the AACR annual meeting 2021
A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies
inMay 01, 2020
Presented at the ASCO annual meeting 2020
NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models
inApr 01, 2020
Presented at the AACR annual meeting 2020
A phase I/II, Open-label, Dose Escalation Followed by Single-arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with R/M HNSCC
inFeb 01, 2020
Presented at the 2020 multidisciplinary Head and Neck Cancers Symposium
NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2, Combined with Chemotherapy or MEK Inhibitor in Gemcitabine-Resistant Pancreatic Tumors, Induced Tumor Regression
inApr 01, 2019
Presented at the 2019 AACR Special Conference Pancreatic Cancer